Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiolabelled OligoG lung deposition study in adults with cystic fibrosis
2013-003774-27Phase 2Completed
- Sponsor
- AlgiPharma
- Start
- Nov 2013
- Modality
- Microbiome-Derived Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of OligoG in cystic fibrosis (CF) (2 arms), sponsored by AlgiPharma. Primary endpoint: Qualitative lung deposition of radiolabelled OligoG. Started Nov 2013; status: completed.
02
Drugs
OligoG
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2013-003774-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003774-27.